Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of Yucan Granules for overt albuminuria in diabetic kidney disease
CTR20253580Phase 2Active
- Sponsor
- Humanwell Innovative Drug R&D Center
- Start
- Sep 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis comparing Yucan Granules high-dose with Placebo (2 arms). Primary endpoint: Proportion of subjects with complete remission. Started Sep 2025; status: active.
02
Drugs
Yucan granules
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on CTR20253580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253580.